MEND-PNPO Phase III Clinical Trial

GVICDS is proud to serve as the Lead CRO for the MEND-PNPO study, a Phase III clinical trial in the neonatal epilepsy space. This program is evaluating a potential treatment for a rare pediatric neurological disorder and involves multinational coordination, along with complex regulatory and operational execution. The study highlights GVICDS’s ability to manage and deliver global clinical programs directly from its headquarters in Manitoba.

CDS brings proven experience running high‑complexity, rare disease clinical trials. As the contract partner for Medicure Inc.’s Phase 3 MEND‑PNPO study, we combined regulatory know‑how, specialized site networks, and patient‑first logistics to keep timelines on track and data quality uncompromised. Let CDS be the operational backbone for your next rare disease program.